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Introduction
Illicit drugs are a major concern for the citizens of Europe, a major threat to the security and health of
European society and a threat to living conditions worldwide.
In December 2004, the European Council unanimously endorsed the EU Drugs Strategy for 2005-2012 (1),
which aims to achieve a high level of protection, well-being and social cohesion by preventing and reducing
drug use.
The adoption of the Strategy in itself gave a clear signal that political concern about drugs across the
European Union transcends the differences in approach that exist among Member States. The Strategy,
implemented by two successive EU Drugs Action Plans, confirmed that all Member States subscribe to the
same set of basic principles: that there should be a balanced approach to reducing the supply and demand
for drugs, which is based first and foremost on the fundamental principles of EU law and, in every regard,
upholds the founding values of the Union: respect for human dignity, liberty, democracy, equality, solidarity,
the rule of law and human rights. The Strategy and its Action Plans aim to protect and improve the
well-being of society and of the individual, to protect public health, to offer a high level of security for the
general public. This should be accompanied by horizontal measures in which drug policy is based on reliable
data regarding the nature and extent of the problem, on — increasingly — cross-border — coordination
and on cooperation with and towards third countries and international organisations. The Strategy and its
Action Plans are also based on the relevant UN Conventions, which are major legal instruments for addres-
sing the world drug problem.
The Drugs Strategy also provides the framework for two consecutive four-year Action Plans. The first
Action Plan (2005-2008) (2) set out over 80 actions to help coordinate major areas of government inter-
vention in the field of illegal drugs, covering public health, law enforcement, customs, criminal justice and
external relations. While implementation is often the responsibility of the Member States, the Commission
plays an active part in facilitating and evaluating the work in progress, in addition to monitoring anti-drug
legislation, such as Council Framework Decision 2004/757/JHA on Illicit Drug Trafficking, on which it will
report in mid 2009. Moreover, guided by the lessons learnt over the past four years, the Commission is now
proposing a second Action Plan (2009-2012) to be endorsed by the Council.
What has the present Action Plan on Drugs achieved so far?
The current Plan states as its ultimate aim to:
‘… significantly reduce the prevalence of drug use among the population and to reduce the social and health
damage caused by the use of and trade in illicit drugs’.
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The evaluation report (1) is a joint effort by the Commission, the Member States, the European Monitoring
Centre on Drugs and Drug Addiction (EMCDDA), Europol, and European NGO networks represented in the
Civil Society Forum. It is the most extensive assessment of the implementation of EU drug policy to date
and shows that the objectives of the present Plan have been partly achieved:
— drug use in the EU remains at high levels. Available data suggest that the use of heroin, cannabis and
synthetic drugs has stabilised or is declining but that cocaine use is rising in a number of Member
States. The total number of people in the EU who have at some time taken drugs (lifetime prevalence)
— is estimated at 70 million for cannabis, at least 12 million for cocaine, 9,5 million for ecstasy, and
11 million for amphetamines, while at least half a million people are known to be receiving substitution
treatment for drugs like heroin (2),
— although there is no reason for complacency, data available for comparable countries in other parts of
the world show that the consumption of cannabis, cocaine, and amphetamines in the EU is significantly
lower than, for instance, in the US. The same is true for the number of reported HIV infections related
to drug injections,
— the evaluation also shows that Member States' drug policies are converging and that there is a shift
towards underpinning national policies with action plans,
— evidence so far shows that the EU is succeeding in at least containing the complex social phenomenon
of widespread substance use and abuse in the population, and that it is increasingly focusing on
measures to address the harm caused by drugs to individuals and society. It is important to note that it
has done so in spite of the fact that over the period under review the world's illicit opiate production
rose sharply and an unprecedented traffic of cocaine has been targeted at the EU. Seen against this back-
ground of sharply increased supply, the EU's record of managing the problem emerges in a more positive
light,
— in terms of international cooperation, there is now better coordination of EU positions in international
fora on drugs, as in the UN's Commission on Narcotic Drugs (CND) for instance. Moreover, the EU's
integrated and balanced approach to drugs is increasingly serving as a model for other countries
worldwide.
The current Action Plan (2005-2008) is an ambitious exercise. While progress has been made in many
areas, weaknesses have also been identified.
Policy coordination problems persist in many areas, and even if the quality of information on the EU situa-
tion regarding drug use, prevention and treatment has consistently improved, considerable knowledge gaps
remain: there is a persistent lack of reliable data on drug supply but also on the scope and outcomes of
drug-related assistance to third countries.
How to increase commitment across society to reduce drug use
Clearly the EU needs to do more to reduce the impact of health, social, developmental, and economic
problems caused by drug use. If millions of Europeans have at some stage taken drugs or are doing so right
now, there is a gap between public policy and public behaviour that no society can afford to ignore.
There is evidence to suggest that one of the more (cost-) effective approaches to deal with drug use is for
public services engaged in prevention, treatment, harm reduction and law enforcement, to work together in
partnership with voluntary organisations and service providers. In other words, an alliance between citizens
and the institutions created by them and for them.
It is time to put the people of Europe at the centre of policy in this field and to get Europe's citizens more
involved. As a first step, the Commission helped set up the European Civil Society Forum on Drugs,
in 2006. To support the implementation of the EU Action Plan on Drugs, the Commission will, during the
life of the next Action Plan, examine ways to mobilise all those who wish to take part for a formal commit-
ment to do what is necessary at their level and with the means at their disposal to reduce the harm that
drugs do to people. An idea to develop in this respect is the formulation of a ‘European Alliance on Drugs’,
which aims to mobilise a broad range of civil society structures that are active both within and outside the
drug field.
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Towards a new Action Plan on Drugs 2009-2012
The EU Drugs Strategy deals with a complex phenomenon that requires a long-term approach to bring
about change. It is centred on the two key dimensions of drug policy, drug demand reduction and drug supply
reduction, complemented by three cross-cutting themes, coordination, international cooperation and information,
research and evaluation.
To support the Strategy, the Commission proposes a new Action Plan on Drugs (2009-2012), which builds
on the existing framework but also on the lessons learned over the past four years. With due regard to
national legislation, it identifies the following priorities:
1. Improving coordination, cooperation and raising public awareness
Coordination and cooperation in the drug field can be strengthened at both European and national level so
that drug policies are relevant to professionals and civil society, while at the same time enabling these struc-
tures to provide feedback to inform policy.
2. Reducing the demand for drugs
We need to further improve the effectiveness of measures to reduce drug use and its consequences by
improving the coverage, quality and effectiveness of demand reduction interventions, i.e. prevention, treat-
ment and harm reduction services. This includes particular attention for vulnerable groups and the preven-
tion of poly-drug use (combined use of illicit and licit substances, including alcohol, volatile substances and
tobacco).
3. Reducing the supply of drugs
We need more effective law enforcement at EU level to counter drug production and trafficking, making full
use of the capacities of Europol and other EU structures. Actions should be based on an intelligence-led
approach that systematically prioritises the suppliers causing the most harm or posing the most serious
threat. The work currently being undertaken to strengthen the links and coherence between the data used
by the various EU JHA entities will be necessary to support this. More coordinated operations via regional
security platforms should be supported. The new platforms should be set up without overlapping and be
compatible with existing structures.
4. Improving international cooperation
The effectiveness of EU, the world's major donor in the struggle for sustainable solutions to the global drug
problem, would benefit greatly from better coordination of national and Community policies. We are ready
to intensify our commitment in the field of international cooperation to this end, while reaffirming that
effective drug control must be based on the concept of a ‘balanced approach’ — emphasizing that illicit
drug cultivation is an important component of drug supply.
5. Improving understanding of the problem
We need to increase our knowledge of all aspects of drug use through more and better coordinated research
and data, including data on drug-related crime and on the way the illicit drug supply market works.
The Action Plan that follows is intended as a framework to implement these priorities and to add European
value where appropriate.
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I. COORDINATION
Main priority: More efficient policy development and implementation
Objective Action Timetable Responsibleparty Indicators Assessment tools
1. Ensure that a balanced and integrated approach is
reflected in national policies and in the EU approach
towards third countries and in international fora
1. Member States and EU Institutions to effectively
coordinate drugs policy to reflect the objectives of
the EU Drugs Strategy 2005-2012 and this Action
Plan
Ongoing MS
COM
Council
Objectives of the EU Drugs
Strategy and Action Plans
included in national policies
Drug policy at EU level reflects
the objectives of the Drugs
Strategy
Commission Progress Review
2. Ensure effective coordination at EU level 2. The Council's Horizontal Drugs Group (HDG), as
the working group with leading and steering
responsibility for drugs in the Council, should
pro-actively coordinate EU drug policy. The HDG
should identify specific areas of work in other
Council working groups and work towards effective
coordination
Ongoing Council Relevant Council Working
Parties (1) inform/involve HDG
actively and vice versa
Report on drug-related work
of Council working groups
to HDG
3. The Commission and Council to ensure coherence
between internal and external drug policy
Ongoing COM
Council
Coherence between internal
and external drug policy
realised
By 2010: COM Communica-
tion on the coherence between
internal and external drug
policy
Commission Communication
on coordination in internal
and external drug policy
4. The Council to examine the state of the drug
problem once a year, on the basis of the Commis-
sion's annual progress review, relevant reports from
the EMCDDA, Europol and Eurojust
Ongoing Council
COM
MS
EMCDDA
Europol
Eurojust
Council conclusions Presidency conclusions
5. Presidency to convene meetings of the national
drugs coordinators or their equivalents on a regular
basis to advance coordination on specific and
urgent issues requiring action. The coordinators to
be invited to contribute to the Council's annual
examination of the state of the drugs problem (see
Action 4 above)
Twice
annually
PRES
MS
Effective impact on policy coor-
dination
Council conclusions
Presidency report to HDG
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3. Ensure effective coordination at national level 6. Taking into account the work on Drugs coordina-
tion mechanisms in all EU Member States made by
EMCDDA, Member States to examine inter-depart-
mental coordination on drugs to ensure that coor-
dinated positions are presented at EU level and that
the objectives of the EU Action Plan are relayed to
the most effective implementing level
Ongoing MS Member States' contributions
in the HDG and other working
groups are coherent
Commission Progress Review
Reitox national reporting's
4. Ensure the participation of civil society in drugs
policy
7. The Commission to seek at least once a year feed-
back on drugs policy from the Civil Society Forum
on Drugs
Ongoing COM Forum meets at least once a
year
Commission reports outcome
to HDG
Commission Progress Review
Reports from Civil Society
Forum on Drugs
8. The Commission to launch an initiative, ‘The
European Alliance on Drugs’, inviting civil society
organisations across the EU (including e.g. schools,
commercial enterprises, public bodies and NGOs)
to participate in a common framework designed to
create public commitment about and to take action
on drug problems in society.
Ongoing COM Wide commitment to Alliance
(COM)
Activity assessment report
9. Member States to involve civil society at all appro-
priate levels of drugs policy, in accordance with
national practices
Ongoing COM
MS
Civil society takes part in
national dialogue
Input received from civil
society
Commission Progress Review
MS report to COM
II. DEMAND REDUCTION
Main priority: To reduce the demand for drugs, and the health and social consequences of drug use by improving the coverage, quality and effectiveness of services of prevention, treatment and harm reduction
Objective Action Timetable Responsibleparty Indicator Assessment tools
5. Prevent the use of drugs and the risks associated
with it
10. To promote innovation in and systematically make
available evidence-based and evaluated universal
prevention programmes and interventions in
different settings (e.g. towards young people in
youth centres, and schools and towards adults in
workplace and prison), aiming to prevent or delay
first use of drugs. Prevention should also cover
poly-drug use (combined use of illicit and licit
substances, in particular alcohol) as well as drugs
and driving
Ongoing MS Increased availability of
evidence-based evaluated pro-
grammes and comprehensive
strategies in MS, including
those targeting first use
Prevalence of youth drug use
& perception of peer drug use
Reitox national reporting's
ESPAD & HBSC surveys on
school children
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6. Prevent high risk behaviour of drug users
— including injecting drug users — through targeted
prevention
11. To further develop early detection and intervention
techniques and implement effective, evaluated selec-
tive prevention for vulnerable groups at high risk of
developing drug problems, including injecting drug
use
Ongoing MS Trends in drug use
Analysis of risk and protective
factors in drug use
Increased availability of out-
come-evaluated, targeted
prevention programmes in MS
PDU key epidemiological
indicator
Reitox national reporting's
12. To further develop and implement effective, evalu-
ated indicative prevention for specific high-risk
groups of (poly-) drug users, by offering
low-threshold access to counselling, problem beha-
viour management and outreach work where
relevant
Ongoing MS Trends in drug use
Analysis of risk and protective
factors in drug use
Increased availability of out-
come-evaluated, targeted
prevention programmes in MS
PDU key epidemiological
indicator
Reitox national reporting's
7. Enhance the effectiveness of drug treatment and
rehabilitation by improving the availability, accessi-
bility and quality of services
13. Increase the effectiveness and spread of evidence-
based drug treatment options covering a variety of
psychosocial and pharmacological approaches,
corresponding to the needs of drug users (including
relevant treatment adapted to new drugs or types
of use)
Ongoing MS Trends in treatment demand
outcome and retention
Increased availability of diversi-
fied and evidence-based treat-
ment in MS
TDI key epidemiological
indicator
Reitox national reporting's
14. To deliver existing and develop innovative rehabili-
tation and social re-integration programmes that
have measurable outcomes
Ongoing MS Increased availability and effec-
tiveness, when possible, of
rehabilitation and reintegration
programmes in MS
Data on availability of social
reintegration
Reitox national reporting's
15. To publicise, where appropriate the existence of
treatment and rehabilitation services and the variety
of options these services offer at national, regional
and local level for potential target audiences
Ongoing MS Information strategies in place
in MS
Public register of services avail-
able (e.g. internet portal)
Reitox national reporting's
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16. To increase the use of, monitor implementation
and further develop effective alternatives to prison
for drug-using offenders
Ongoing MS Increased availability of ATP
ATP implementation monitored
(COM)
8. Enhance the quality and effectiveness of drug
demand reduction activities, taking account of
specific needs of drug users according to gender,
cultural background, age, etc.
17. To develop, implement and exchange good practice
guidelines/quality standards for prevention, treat-
ment, harm reduction and rehabilitation interven-
tions and services
2009-2012 MS
COM
EMCDDA
Existence of relevant guidelines
and/or quality standards
Level of implementation of
guidelines and/or standards
Commission Progress Review
Reitox national reporting's
18. Member States to survey the availability and effec-
tiveness of prevention, treatment, harm reduction
and rehabilitation services, in responding to specific
needs, on the basis of a methodological framework
to be developed by the Commission — with the
support of the EMCDDA — and that is compatible
with existing methodologies
2012 MS
COM
EMCDDA
Methodological framework for
the survey developed
Number of Member States that
complete the survey
COM inventory of MS survey
reports
19. To develop an EU consensus on minimum quality
standards and bench-marks for prevention, treat-
ment, harm reduction and rehabilitation interven-
tions and services taking into account needs of
specific groups and the work done at national and
international level
2012 MS
Council
COM
EMCDDA
Development of the consensus
on quality standards and
benchmarks for prevention,
treatment, harm reduction and
rehabilitation interventions and
services
COM proposal on EU
consensus
Council conclusions
20. To develop, as appropriate, services for minorities,
including, for example, migrants
Ongoing MS Availability of relevant services Reitox national reporting's
9. Provide access to health care for drug users in prison
to prevent and reduce health-related harms asso-
ciated with drug abuse
21. To develop and implement prevention, treatment,
harm reduction and rehabilitation services for
people in prison, equivalent to services available
outside prison. Particular emphasis to be placed on
follow-up care after release from prison
Ongoing MS Drug policies and interventions
implemented specifically for
delivery of drug services in
prison and follow-up of
ex-prisoners
Decrease in drug-related health
problems in prison
Commission Progress Review
Reitox national reporting's
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22. Member States to endorse and implement in prison
settings indicators to monitor drug use,
drug-related health problems and drug services
delivery on the basis of a methodological frame-
work developed by the Commission — with the
support of the EMCDDA that is compatible with
existing methodologies, and taking into account the
work done by the UNODC (in the project area of
HIV/AIDS and treat.net) and by WHO (Health in
prisons)
Ongoing MS
COM
EMCDDA
Indicator to monitor drug use,
drug-related health problems
and drug services conceived
and implemented
Report on progress
Standardised monitoring
protocol for prison drug
situation & responses
10. Ensure access to harm reduction services, in order to
reduce the spread of HIV/AIDS, hepatitis C and other
drug-related blood-borne infectious diseases and to
reduce the number of drug-related deaths in the EU
23. To provide access to, and improve coverage of,
harm reduction services and the variety of options
these services offer options as an integral part of
drug demand reduction, making use of interven-
tions of proven effectiveness where available (2)
Ongoing MS COM to report on progress
Decrease in drug-related infec-
tious diseases
Decrease in number of
drug-related deaths
Improved coverage of harm
reduction services
COM follow-up survey of
CR 2003/488/EC
DRID key epidemiological
indicator
DRD key epidemiological
indicator
III. SUPPLY REDUCTION
Main priority: A measurable improvement in the effectiveness of law enforcement in the field of drugs at EU level. Europol, Eurojust and other EU structures to fully exercise the respective roles for which they were
created, in the interest of efficiency, EU compatibility of national initiatives, intra-EU coordination, and economies of scale
Objective Action Timetable Responsibleparty Indicator Assessment tools
11. Enhance effective law enforcement cooperation in
the EU to counter drug production and trafficking
24. To target criminal organisations and emerging
threats, using an intelligence-led approach (based
on the European Criminal Intelligence Model
(ECIM) methodology) that prioritises the criminal
networks and markets that pose the most serious
threats
Ongoing MS
Europol
Eurojust
Council
Number of criminal organisa-
tions posing serious threats
that are targeted by MS using
the ECIM concept
Number and nature of emer-
ging threats (such as new
drugs, new trafficking routes
and methods, new manufac-
turing methods) identified
EU Organised Threat Assess-
ment (OCTA) (and subse-
quent Council conclusions
setting EU priorities for
the fight against organised
crime)
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25. Multidisciplinary law enforcement operations,
involving Europol and Eurojust, as well as police,
customs and border control services, will be used
to a greater extent through bilateral and multilateral
cooperation initiatives, joint investigation teams
(JIT) and joint customs operations (JCO). Member
States will examine which measures are possible to
facilitate and speed up the process and encourage
greater use of these instruments in drugs cases
Ongoing MS
Europol
Eurojust
Number and outcome of
drug-related bilateral and multi-
lateral cooperation initiatives,
JITs and JCOs
Number of MS involved
Commission Progress Review
MS reports to COM
Assessment report on results
achieved
26. To improve the quality of intelligence data provided
via Europol National Units to Europol and its
related projects including Analysis Work Files
(AWF). The emphasis should be on the serious
organised crime and cooperation from those
Member States most highly impacting upon the
wider EU drug markets
2012 MS
Europol
Report of Europol assessing the
quantity and quality of data
received
Commission Progress Review
Europol assessment report
27. Implementation of drugs related COSPOL projects,
paying special attention to:
— the input of appropriate levels of expertise in
COSPOL meetings,
— the value added in terms of appropriate intelli-
gence and investigation capacity, and making
appropriate use to this end of already existing
or future Analytical Work Files (AWF)
2012 MS
Europol
Expertise of Member States
represented at management
meetings and the seniority of
MS representation
Report of COSPOL drivers
assessing the increase in identi-
fiable operational results
Commission Progress Review
MS reports to COM
28. The European Police College (CEPOL) (3) to provide
relevant advanced training (4) for senior police and
customs officers and for liaison officers in
3rd countries through national police training
colleges
Ongoing CEPOL
MS
Curriculum developed for drug
law enforcement
Additional relevant training
included in CEPOL AWP
Number of training courses
Number of officers trained
Curriculum published
CEPOL annual report
Commission Progress Review
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29. To make more systematic use of Member State
liaison officers and liaison magistrates, where
appropriate, in third countries for the exchange of
information and intelligence between MS
law enforcement agencies and Europol taking into
account the Council Decision 2003/170/JHA of the
27 February 2003 on the common use of liaison
officers posted abroad by the law enforcement
agencies of the Member States in the version of
24 July 2006, Council Decision 2006/560/JHA
Ongoing MS
Europol
Eurojust
Increase in international opera-
tional law enforcement coop-
eration reported by Member
States, Europol, Eurojust
Number of international law
enforcement cooperations
Commission Progress Review
Evaluation report on MS,
Europol and Eurojust contri-
butions
30. To adopt and implement an EU-wide system for the
forensic profiling in relation to drugs law enforce-
ment for synthetic drugs and for other drugs,
where appropriate, drawing on, inter alia, the experi-
ence gained through projects such as SYNERGY and
CHAIN, the structure and expertise of Europol and
the Commission's Joint Research Centre, and
ongoing MS law enforcement activities and experi-
ences in this area
Ongoing MS
COM
Europol
System or systems in place 2012 Progress Review
(including the assessment of
value)
12. Enhance effective judicial cooperation in the area of
combating drug trafficking and law enforcement as
regards production, trafficking of drugs and/or
precursors, and money laundering related to this
traffic
31. To encourage the full use of the existing EU instru-
ments on mutual assistance requests in criminal
matters, of European arrest warrants, and of sanc-
tions issued by MS jurisdictions
Ongoing MS
COM
Eurojust
Report on best practices and
recommendations
Increase in number of mutual
assistance requests
Increase in number of
European arrest warrants
Other indicators to be devel-
oped (cf. Action 61)
COM assessment of Council
Framework Decision 2004/
757/JHA of 25 October
2004 laying down minimum
provisions on the constituent
elements of criminal acts
and penalties in the field of
illicit drug trafficking
COM progress review (new
indicators)
32. Member States to consider, where appropriate, to
develop witness protection programmes and to
explore the potential added value of joint coopera-
tion in this field
2012 MS
COM
Eurojust
Existing national legislation Final report by the Presi-
dency 20.12.2008
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33. To strengthen the cooperation among EU Member
States in order to achieve the full application of the
legal instruments relating to mutual recognition of
confiscation orders
Ongoing MS
COM
Council
Eurojust
Europol
COM Communication adopted
Assessments of assets seized
Commission Progress Review
MS reports to COM on
assets seized
34. To support the establishment of effective Asset
Recovery Offices in the Member States in accord-
ance with the Council Decision 2007/845/JHA and
to further support the Member States involved
through the CARIN network. To support investiga-
tions through Europol and related Europol AWFs
Ongoing COM
MS
Europol
Eurojust
Increase in number of
supported investigations relat-
ing to asset tracing and identifi-
cation
Increase in number and value
of cash and assets confiscated
Commission Progress Review
COM implementation re-
port on Council Decision
2007/845/JHA
13. Respond rapidly and effectively at operational, policy
and political levels to emerging threats (e.g. emerging
drugs, new routes)
35. To set up, where necessary, regional security plat-
forms (e.g. MAOC-N, Baltic Sea TF) to counter
emerging threats by means of coordinated opera-
tional responses. Such action to be compatible with
existing legal and operational arrangements at
EU level and based on specific threat assessments
(see also Action 48). New platforms should be set
up without overlapping and be compatible with
existing structures
Ongoing MS
Council
Europol
COM
Response measures to pro-
actively handle risk and mini-
mise threats have been put in
place in relatively short time
frame
Increase in number of criminal
operations disrupted (seizures,
changing trafficking behaviour)
Reports by regional security
platforms
Assessment report by MS
concerned to Council
Security platforms evaluation
report
36. The EU to focus on coordinated and joint efforts
between the Member States and regions most
highly exposed to particular drug production/traf-
ficking phenomena, in cooperation with Europol as
appropriate
Ongoing MS
Europol
Eurojust
Council
Operational and strategic
outcomes of MS action taken
Commission Progress Review
MS reports to COM
14. Reduce the manufacture and supply of synthetic
drugs
37. Member States to actively maintain law enforce-
ment cooperation/joint operations in this area and
to share intelligence and best practices. Optimal use
to be made of Europol's Analytical Work File
SYNERGY, its components (5) and the associated
EJUP and COSPOL initiatives
Ongoing MS
Europol
Eurojust
Outcomes of joint projects
initiated/completed
Dismantled production facilities
reported to EILCS
Number of SYNERGY reports
generated
Commission Progress Review
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15. Reduce the diversion and trafficking in/via the EU of
drug precursors used for the manufacturing of illicit
drugs
38. The EU to develop a clear and unified position on
this matter at international level and in the relevant
international fora, based on existing legislation and
cooperative practices with the private sector
through effective coordination through the relevant
Council committees
Ongoing COM
Council
MS
Joint EU positions in interna-
tional fora
Commission Progress Review
COM report on all practices
39. Customs and border control services to integrate
precursor controls at a strategic level, enhancing
the effectiveness of border control management
through implementing the Community Risk
Management, and to coordinate more closely with
other law enforcement agencies engaged in
combating drug production and trafficking
Ongoing MS Improvement in precursor
control, detection, seizure and
profiling situation compared
with 2008
Drawing up of profiles for the
determination of chemical
precursors
Commission Progress Review
MS report to COM
40. The EU to give full support to international opera-
tional cooperation aimed at preventing the diver-
sion of drug precursors, such as the INCB-led
projects PRISM and COHESION. The operational
cooperation among the investigation authorities
within the EU is to be supported by the EJUP coop-
eration framework and the Europol-AWF co-opera-
tion framework. This cooperation framework
should be further intensified/utilised
Ongoing COM
MS
Increase in number of stopped
and/or seized shipments
Commission Progress Review
41. From a law enforcement and intelligence-led
perspective, the EU and Members States to fully
support Europol's drug related projects and EJUP,
with a view to combating criminal networks
involved in precursor trafficking
Ongoing MS
EJUP
Europol
Increase of reporting to
Europol projects on precursors
trafficking by MS and EJUP
MS and EJUP Progress
Report
42. To evaluate EU drug precursor control legislation
and its implementation
Ongoing COM
MS
Conclusion of the evaluation Report published 20.12.2008
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43. The EU to develop and exploit, where possible in
consultation with Europol, cooperation agreements
with principal identified source countries of main
synthetic drug precursors
Ongoing COM Agreements established
Reduction of illicit shipments
of drug precursors from the
countries concerned
Commission Progress Review
MS Reports to COM
44. The Commission, OLAF, Europol, EJUP and
COSPOL to enhance inter-disciplinary cooperation,
with a view to establishing joint initiatives.
Ongoing COM
MS/EJUP
Europol
Number of interdisciplinary
meetings/joint initiatives estab-
lished
Commission Progress Review
IV. INTERNATIONAL COOPERATION
Main priority: Improve the effectiveness of EU cooperation with third countries and international organisations in the field of drugs through closer coordination of policies within the EU. Promoting the consistent
projection worldwide of the European balanced approach to the drugs problem
Objective Action Timetable Responsibleparty Indicator Assessment tool
16. Systematically include EU drug policy concerns in
relations with third countries and regions where
appropriate and within the broader development and
security agenda. To do so on the basis of strategic
planning and coordination between all actors
concerned
45. To ensure that EU relations with third countries
reflect the objectives of the EU Drugs Strategy and
Action Plans
Ongoing MS
COM
Drug policy priorities increas-
ingly reflected in relations with
third countries
Agreements, strategy papers,
action plans, etc.
Commission Progress Review
46. To improve the effectiveness of existing frameworks
on drugs such as the Cooperation and Coordination
Mechanism between the EU and LAC, the
EU-Andean Specialised Dialogue and of ‘Drug
Troikas’ with third countries and regions, by identi-
fying specific areas of cooperation and establishing
outcome indicators
Ongoing Council
COM
Cooperation initiatives estab-
lished and implemented
Commission Progress Review
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47. In line with the EU's political decisions and strate-
gies and with the support of the MS and EC assis-
tance programmes, to address drug-related concerns
in producer countries and those along (emerging)
trafficking routes, such as West Africa, through
projects aimed at reducing the demand for and the
supply of drugs, including measures of alternative
development, and preventing the diversion of
chemical precursors. The assistance is to be coordi-
nated, where appropriate, to the drug action plans
between the EU and third countries and regions
(see Actions 51 and 60)
Ongoing COM
MS
Drug policy priorities reflected
in projects funded
Projects funded reflect balance
between demand and supply
reduction
Synergies established between
MS and EC funding
programmes
Commission Progress Review
48. To step up regional and intra-regional cooperation
to reduce the demand for and supply of drugs in
third countries with the support of MS and
EC funding programmes, such as the Development
Cooperation Instrument and the European Develop-
ment Fund, the Instrument for Stability and the
European Neighbourhood Policy Instrument
Ongoing COM
MS
New inter-regional cooperation
initiatives established and
implemented
Synergies established between
MS and EC funding
programmes
Increase in number and overall
budget of projects funded
Commission Progress Review
49. In the interest of coordination, to establish a moni-
toring mechanism on EU drug-related assistance
given to third countries
Annual Council
MS
COM
Mechanism established
Annual reports by this
mechanism
Overview of drug-related EC
and MS projects in third coun-
tries
Commission Progress Review
50. To carry out a survey of the scope and outcome of
EC drug-related projects in 3rd countries
2010 COM Survey carried out COM survey report
published
51. To update and implement the EU Drug Action
Plans for the Central Asian Republics (6); Latin
America and the Caribbean (7); and Western
Balkans and Candidate Countries (8)
Ongoing MS
COM
Priorities identified
Level of implementation of the
Action Plans
Commission Progress Review
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52. Utilise the Dublin Group consultative mechanism
and maintain an active dialogue with third coun-
tries for the implementation of Mini Dublin
Groups' recommendations
Ongoing MS
COM
Dublin
Group
Number of Dublin Group
recommendations implemented
Dublin Group Reports
17. Promote and implement the EU approach to
alternative development (as defined in doc-
ument 9597/06 CORDROGUE 44 and
UNODC/CND/2008/WG.3/CRP.4) in cooperation
with third countries, taking into account human
rights, human security and specific framework
conditions
53. To intensify the financial support for the implemen-
tation of alternative development projects and
programmes, making certain that interventions are
properly sequenced and that development assis-
tance is not conditional on reductions of illicit drug
crop cultivation and finance initiatives for the
prevention of illicit drug crop cultivation
Ongoing MS
COM
Number of projects and
programmes funded in line
with the EU approach on Alter-
native development (9598/06
CORDROGUE 44 and
UNODC/CND/2008/WG.3/
CRP.4)
Reported decrease in illicit drug
crop cultivation and increase of
social and economic develop-
ment at the primary stake-
holder level (9) in third coun-
tries financially supported from
EU funds
(Project/Programmes) Agree-
ments
Internal Project and
Programme Monitoring and
Evaluation system and
reports
National Statistics of third
countries
MS Reports to COM
54. To include alternative development into the broader
development agenda of Member States and encou-
rage third countries to integrate alternative develop-
ment in their national policies
Ongoing MS
COM
National policies, strategies and
action plans reflecting drug
issues
Poverty Reduction Strategies
(PRSP),Country Assistance
Strategies CAS), National
Development Strategies,
(National) Action Plans
MS Reports to COM
55. To contribute to initiatives within a drugs environ-
ment aiming at the reduction of poverty, conflict
and vulnerability by supporting legal, viable and
sustainable livelihoods
Ongoing MS
COM
Number of supported initia-
tives
Impact of the supported initia-
tives on the sustainability of
legal livelihood systems:
— food security and income
generation of the poor are
increased,
— access of poor people to
social and productive infra-
structure are improved
Number of evaluated projects
that have shown positive
impact
Initiatives
MS Reports to COM
Internal Project and
Programme Monitoring and
Evaluation system and
reports
Baseline Surveys imple-
mented by WHO, WFP, FAO
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18. Strengthen EU coordination in the multilateral
context and promote an integrated and balanced
approach
56. To ensure better coordination and continuity
between the HDG and MS delegations to the United
Nations Commission on Narcotic Drugs (CND),
including through the appropriate burden-sharing
among Member States on the initiative of the
Presidency
2009 Council
PRES
MS
Coordination between Vienna
delegations and HDG strength-
ened
Commission Progress Review
57. To prepare, coordinate and adopt EU common
positions and joint resolutions in the CND
Ongoing PRES
MS
COM
Council
Number of joint EU resolutions
EU common positions
supported by other regions
Commission Progress Review
Convergence Indicator
(9099/05 CORDROGUE 27)
58. To present an EU position in the high-level segment
of the 52nd CND on the evaluation of and follow-
up to UNGASS '98 (10), reflecting the fundamental
principles of EU drugs policy
2009 Council
MS
COM
Inclusion of the EU's positions
in the UN Political Declaration
Commission Progress Review
59. To coordinate activities with other international
fora or programmes, in particular UNODC,
Pompidou Group, WHO, UNAIDS, WCO and
Interpol
Ongoing MS
COM
Regular mutual information on
activities in appropriate fora, in
particular at HDG meetings
Coordination strengthened
Commission Progress Review
19. Support the candidate and stabilisation and associa-
tion process countries
60. To provide the necessary technical and other assis-
tance to these countries to familiarise them with
the EU acquis in the field of drugs and to assist
them in carrying out the required actions, including
those adopted in the drug action plan with the
Western Balkans (11)
Ongoing MS
COM
Council
EMCDDA
Europol
Countries increasingly comply-
ing with EU acquis
Number and quality of projects
completed
Advancement of dialogue
and/or cooperation with rele-
vant EU agencies
Level of implementation of
action plans
Commission Progress Review
Country reports
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20. To improve cooperation with European Neighbour-
hood Policy countries
61. To improve the dialogue on drugs with European
Neighbourhood Policy countries in a bilateral or
regional context, in particular through existing
subcommittees
Ongoing MS
COM
Effective result of dialogue Commission Progress Review
62. The Commission to encourage these countries to
use the European Neighbourhood Policy Instrument
to implement the drug sections of the ENP Action
Plans
Ongoing COM Number of drug-related
projects implemented under
the ENP Instrument
Commission Progress Review
V. INFORMATION, RESEARCH, & EVALUATION
Main priority: Improving the understanding of all aspects of the phenomenon of drug use in order to expand the knowledge base for public policy and raise awareness among citizens of the social and health impli-
cations of drug use, and to carry out research
Objective Action Timetable Responsibleparty Indicator Assessment tools
21. Expand the knowledge base in the field of drugs by
promoting research
63. The Council and Commission to:
— identify future EU research priorities in the field
of illicit drugs and the mechanisms needed in
order to generate new knowledge,
— develop new approaches and technologies,
— strengthen research capability by developing
and focusing its strategic direction and taking
steps to improve cooperation in the EU
2009 MS
COM
EMCDDA
Council
Research priorities established
Mechanisms identified and put
in place
COM proposal on research
in EU
Council Conclusions
22. Ensure the exchange of accurate and policy-relevant
information in the field of illicit drugs
64. Member States to provide Reitox (12) National Focal
Points (NFP) with the necessary resources to meet
the obligations and quality standards of EMCDDA
membership. NFPs to contribute to the EMCDDA
on the basis of annual agreements and with appro-
priate support from the EMCDDA
Ongoing MS
EMCDDA
Exchange of data required
for monitoring & evaluation
purposes
Level of Reitox funding and
other resources match require-
ments
NFPs contribute according to
agreed standards
EMCDDA annual report on
NFP capacity
Reitox national reporting's
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23. Further develop instruments to monitor the drug
situation and the effectiveness of responses to it
65. To further improve and fully implement the five
EMCDDA key epidemiological indicators and the
development of new indicators and measures in
drug demand reduction
2012 MS
EMCDDA
COM
Increase compliance of MS
with implementation criteria
for key indicators
Improvement in treatment
demand and problem use (13)
indicators
Indicators/measures for rehabi-
litation and reintegration
Measures in drug demand
reduction
Number of MS that have
fully implemented Treatment
Demand Indicator
EMCDDA compliance report
COM services paper on
drug-related data
66. To conduct a scientific study to assess the use of
the internet as a tool in relation to illicit drug traf-
ficking and to analyse which national, European
and/or international measures may be effective to
counteract
2010 MS
COM
Outcomes of the scientific
study
Report of the study by COM
67. To develop key-indicators for the collection of
policy-relevant data on drug-related crime, illegal
cultivation, drug markets and supply reduction
interventions and to develop a strategy to collect
them
Ongoing COM
EMCDDA
Europol
MS
Key indicators identified
Implementation strategy devel-
oped
COM services paper on
drug-related data
68. To develop analytical instruments to better assess
the effectiveness and impact of drug policy
(e.g. model evaluation tools, policy effectiveness
indices, public expenditure analysis, etc.)
2010 COM
EMCDDA
MS
Analytical instruments devel-
oped
More accurate analysis of drug
situation
COM studies
EMCDDA
69. To assess the functioning of Council Decision
2005/387/JHA on the information exchange, risk
assessment and control of new psychoactive
substances, and amend, if necessary
2010 COM
Council
EMCDDA
Europol
EMEA
Assessment conducted
Possible amendment proposed
Assessment report
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24. Ensure the ongoing evaluation of drug policy 70. Member States to evaluate and fine-tune national
drug policies on a regular or ongoing basis
Ongoing MS Number of countries that have
evaluated drug policies
MS evaluation reports
published
71. To present an annual progress review to the
Council and the European Parliament on the imple-
mentation of the Action Plan, and to present
adapted/improved indicators and reporting mechan-
isms for monitoring and evaluation where appro-
priate and necessary
Annual COM
EMCDDA
Europol
MS
Council
Annual progress review deliv-
ered
Availability of relevant indica-
tors
Commission Progress Review
72. To have an external, independent assessment
carried out of the implementation of the EU Drugs
Strategy 2005-2012 and EU Drugs Action Plan
2009-2012, followed by a reflection period prior
to follow-up
2012 COM
Council
MS
Assessment of achievement of
individual actions
The impact on the overall drug
situation is known
External evaluation report
published
(1) These Council Working Parties include: Police and Customs Working Parties, the Multidisciplinary Group on Organised Crime, the Health Working Group, External Affairs Working Groups and the Economic Issues Working Group.
(2) This action builds on the Council Recommendation 2003/488/EC on the prevention and reduction of health-related harm associated with drug dependence.
(3) European Police College; Council Decision 2005/681/JHA.
(4) Including dismantling of illicit drug laboratories.
(5) Project SYNERGY includes the Analysis Work File (AWF), the Europol Illicit Laboratory Comparison System (EILCS) and the Ecstasy Logo System, the latter incorporated within the general Europol Synthetic Drugs Seizure System (ESDSS).
(6) 12353/02 CORDROGUE 78 CODRO 1 NIS 107.
(7) 7163/1/99 REV 1 CORDROGUE 19 CODRO 2; Port of Spain Declaration — 10451/07 CORDROGUE 34 COLAT 9 AMLAT 54.
(8) 5062/2/03 REV 2 CORDROGUE 3 COWEB 76 + COR 1.
(9) 13501/1/08 REV 1 CORDROGUE 71 UD 172, Annex III.
(10) Political Declaration (resolution S-20/2, Annex) of the twentieth Special Session of the United Nations General Assembly.
(11) 5062/2/03 REV 2 CORDROGUE 3 COWEB 76 + COR 1.
(12) Réseau Européen d'Information sur les Drogues et les Toxicomanies.
(13) EMCDDA indicator to be brought in line with criteria of public health relevance (such as intensity of use and health consequences) including international classifications (DSM-V/ICD-10).
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